Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy and safety of Suptavumab (REGN2222) for preventing medically attended RSV infections in preterm infants has completed and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Suptavumab (REGN2222)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2018-11-06